Department of Medicine, St Joseph's Healthcare Hamilton, McMaster University, Hamilton, ON, Canada.
Hematol Oncol Clin North Am. 2010 Aug;24(4):683-94, vii-viii. doi: 10.1016/j.hoc.2010.05.008.
Given the known increased risk of venous thromboembolism (VTE) associated with both oral contraceptive (OC) use and hormone replacement therapy (HRT), it is important to address questions about the prevention and management of hormone-associated VTE. Specifically, the objectives of this article are as follows: (1) to provide suggested clinical management approaches for the primary and secondary prevention of VTE for women with thrombophilia; (2) to provide suggested clinical management approaches for the primary and secondary prevention of VTE in the perioperative period for women taking OC or HRT; and (3) to provide practical management approaches for frequently encountered clinical scenarios relating to duration of treatment for hormone-associated VTE.
鉴于口服避孕药（OC）和激素替代疗法（HRT）均与静脉血栓栓塞症（VTE）风险增加相关，因此重要的是要解决与激素相关的 VTE 的预防和管理问题。具体而言，本文的目的如下：（1）为血栓形成倾向女性的 VTE 一级和二级预防提供建议的临床管理方法；（2）为服用 OC 或 HRT 的女性围手术期 VTE 的一级和二级预防提供建议的临床管理方法；（3）为与激素相关的 VTE 治疗持续时间相关的常见临床情况提供实用的管理方法。
